Stable transgene expression in primitive human CD34+ hematopoietic stem/progenitor cells, using the Sleeping Beauty transposon system.
Sleeping Beauty (SB) transposon-mediated integration has been shown to achieve long-term transgene expression in a wide range of host cells. In this study, we improved the SB transposon-mediated gene transfer system for transduction of human CD34(+) stem/progenitor cells by two approaches: (1) to increase the transposition efficacy, a hyperactive mutant of SB, HSB, was used; (2) to improve the expression of the SB transposase and the transgene cassette carried by the transposon, different viral and cellular promoters were evaluated. SB components were delivered in trans into the target cells by Nucleoporation. The SB transposon-mediated integration efficacy was assessed by integrated transgene (enhanced green fluorescent protein [eGFP]) expression both in vitro and in vivo. In purified human cord blood CD34(+) cells, HSB achieved long-term transgene expression in nearly 7-fold more cells than the original SB transposase. Significantly brighter levels of eGFP expression (5-fold) were achieved with the human elongation factor 1alpha (EF1-alpha) promoter in Jurkat human T cells, compared with that achieved with the modified myeloproliferative sarcoma virus long terminal repeat enhancer-promoter (MNDU3); in contrast, the MNDU3 promoter expressed eGFP at the highest level in K-562 myeloid cells. In human CD34(+) cord blood cells studied under conditions directing myeloid differentiation, the highest transgene integration and expression were achieved using the EF1-alpha promoter to express the SB transposase combined with the MNDU3 promoter to express the eGFP reporter. Stable transgene expression was achieved at levels up to 27% for more than 4 weeks of culture after improved gene transfer to CD34(+) cells (average, 17%; n = 4). In vivo studies evaluating engraftment and differentiation of the SB-modified human CD34(+) cells demonstrated that SB-modified human CD34(+) cells engrafted in NOD/SCID/gamma chain(null) (NSG) mice and differentiated into multilineage cell types with eGFP expression. More importantly, secondary transplantation studies demonstrated that the integrated transgene was stably expressed in more primitive CD34(+) hematopoietic stem cells (HSCs) with long-term repopulating capability. This study demonstrates that an improved HSB gene transfer system can stably integrate genes into primitive human HSCs while maintaining the pluripotency of the stem cells, which shows promise for further advancement of non-virus-based gene therapy using hematopoietic stem cells.
Sumiyoshi
Teiko
T
Division of Research Immunology/Bone Marrow Transplantation, Saban Research Institute of Childrens Hospital Los Angeles, Los Angeles, CA 90027, USA.
Holt
Nathalia G
NG
Hollis
Roger P
RP
Ge
Shundi
S
Cannon
Paula M
PM
Crooks
Gay M
GM
Kohn
Donald B
DB
D000818:Animals; D018952:Antigens, CD34 / Q000276:immunology; D002469:Cell Separation; D004251:DNA Transposable Elements; D005312:Fetal Blood / Q000166:cytology; D015870:Gene Expression; D018014:Gene Transfer Techniques; D015316:Genetic Therapy / Q000379:methods*; D049452:Green Fluorescent Proteins / Q000235:genetics; D018380:Hematopoietic Stem Cell Transplantation; D006412:Hematopoietic Stem Cells / Q000378:metabolism*; D006801:Humans; D019169:Jurkat Cells; D051379:Mice; D016513:Mice, SCID; D019076:Transgenes; D019895:Transposases / Q000235:genetics*
D018952:Antigens, CD34; D004251:DNA Transposable Elements; C485184:enhanced green fluorescent protein; D049452:Green Fluorescent Proteins; D019895:Transposases; C494471:sleeping beauty transposase, human
Lab Invest. 1993 Jun;68(6):676-86
8515654
Stem Cells. 2001;19(6):492-9
11713340
J Clin Invest. 2000 Apr;105(7):1013-21
10749580
Blood. 1995 Nov 15;86(10):3745-53
7579341
Blood. 2009 Aug 13;114(7):1319-30
19414858
Nat Protoc. 2007;2(7):1692-704
17641634
Mol Ther. 2008 Feb;16(2):359-69
18071335
J Biol Chem. 1989 Apr 5;264(10):5791-8
2564392
Mol Ther. 2007 Jan;15(1):139-45
17164785
Mol Ther. 2000 Nov;2(5):458-69
11082319
Mol Ther. 2007 Jan;15(1):10-2
17164769
Nat Med. 2006 Apr;12(4):401-9
16582916
Nat Biotechnol. 2005 Aug;23(8):967-73
16082368
Stem Cells Dev. 2006 Apr;15(2):278-85
16646674
Bone Marrow Transplant. 2001 Jun;27(11):1201-9
11551032
Mol Ther. 2004 Feb;9(2):147-56
14759798
Mol Ther. 2003 Jan;7(1):112-21
12573624
Exp Hematol. 1999 Jun;27(6):1019-28
10378891
Nat Genet. 2000 May;25(1):35-41
10802653
Transgenic Res. 1999 Jun;8(3):223-35
10478492
J Virol. 2004 Jun;78(12):6556-66
15163748
Mol Cell Biol. 2007 Mar;27(6):2048-58
17242210
Dev Biol. 1992 Oct;153(2):396-401
1383066
Stem Cells. 2008 Jun;26(6):1436-43
18323409
J Virol. 1996 May;70(5):3207-14
8627801
Science. 1999 Jan 29;283(5402):682-6
9924027
J Mol Biol. 2002 May 17;318(5):1221-35
12083513
Mol Ther. 2008 Mar;16(3):439-49
18227842
Blood. 2005 Sep 1;106(5):1565-73
15920010
J Mol Biol. 2005 Feb 11;346(1):161-73
15663935
Nat Biotechnol. 2007 Nov;25(11):1298-306
17965707
Blood. 2002 Nov 1;100(9):3175-82
12384415
J Mol Biol. 2000 Sep 8;302(1):93-102
10964563
Cell. 1997 Nov 14;91(4):501-10
9390559
Mol Ther. 2006 Oct;14(4):505-13
16905365
Gene Ther. 2009 Jun;16(6):724-33
19262614
Science. 2002 Jun 28;296(5577):2410-3
12089448
Methods Mol Biol. 2008;435:165-73
18370075
Blood. 2006 Jan 15;107(2):483-91
16189271
J Neurosci Res. 2009 Jan;87(1):289-300
18756516
N Engl J Med. 2009 Jan 29;360(5):518-21
19179320
Genetica. 1997;100(1-3):177-84
9440271
J Virol. 2003 Sep;77(17):9439-50
12915559
Gene Ther. 1999 May;6(5):715-28
10505094
Curr Opin Pharmacol. 2005 Oct;5(5):513-9
16084771
IUBMB Life. 2007 Jun;59(6):374-9
17613167
Nucleic Acids Res. 1990 Sep 11;18(17):5322
1698283
Mol Ther. 2002 Nov;6(5):615-26
12409260
J Cell Mol Med. 2007 May-Jun;11(3):521-30
17635643
Hum Gene Ther. 1998 Oct 10;9(15):2197-205
9794204
Mol Cell Biol. 2005 Mar;25(6):2085-94
15743807
PLoS Comput Biol. 2006 Nov 24;2(11):e157
17166054
Science. 2000 Apr 28;288(5466):669-72
10784449
Exp Hematol. 2006 Oct;34(10):1333-43
16982326
Nat Med. 2006 Mar;12(3):348-53
16491086
Nat Protoc. 2007;2(12):3146-52
18079714
FEBS Lett. 2005 Nov 7;579(27):6205-9
16243318
Methods. 2002 Oct;28(2):227-36
12413421
Mol Ther. 2005 Dec;12(6):1148-56
16150650
Proc Natl Acad Sci U S A. 1992 Jan 1;89(1):89-93
1729724
J Virol. 2000 Feb;74(3):1286-95
10627539
Cell Cycle. 2006 Jun;5(12):1275-80
16775431
Cell. 1985 Jun;41(2):521-30
2985280
Stem Cells. 2007 Nov;25(11):2919-27
17673526
Hum Gene Ther. 2007 Sep;18(9):849-60
17767401
Blood. 1999 Nov 15;94(10):3349-57
10552944
Nat Protoc. 2007;2(12):3153-65
18079715
Blood. 1998 Jun 15;91(12):4600-7
9616156
Mol Ther. 2006 Jun;13(6):1121-32
16556511
Genetics. 1998 May;149(1):179-87
9584095
Science. 2003 Jan 24;299(5606):495
12543948
Science. 2003 Oct 17;302(5644):415-9
14564000
Mol Cell Biol. 2004 Oct;24(20):9239-47
15456893
Adv Genet. 2005;54:189-232
16096013
Genetics. 1996 Nov;144(3):1087-95
8913752
Science. 2003 May 2;300(5620):763
12730593
Proc Natl Acad Sci U S A. 1991 Jun 1;88(11):4626-30
1905011
Mol Ther. 2003 Jul;8(1):108-17
12842434
N Engl J Med. 2001 Mar 22;344(12):881-8
11259721
Nat Protoc. 2008;3(12):1932-40
19180077